Trinity Biotech (NASDAQ:TRIB) Earns Buy Rating from Analysts at StockNews.com

Analysts at StockNews.com initiated coverage on shares of Trinity Biotech (NASDAQ:TRIB) in a report released on Friday. The firm set a “buy” rating on the stock.

Trinity Biotech Stock Up 5.4 %

Shares of NASDAQ TRIB opened at $2.14 on Friday. The business has a fifty day simple moving average of $1.98 and a 200-day simple moving average of $2.14. The company has a market cap of $16.31 million, a price-to-earnings ratio of -0.77 and a beta of 1.31. Trinity Biotech has a 12 month low of $1.49 and a 12 month high of $5.50.

Trinity Biotech (NASDAQ:TRIB) last posted its quarterly earnings data on Thursday, May 23rd. The company reported ($0.37) EPS for the quarter. As a group, sell-side analysts expect that Trinity Biotech will post -2.17 EPS for the current fiscal year.

About Trinity Biotech

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.